Radiolabelled minigastrin (MG) analogues targeting the cholecystokinin-2 receptor (CCK2R), overexpressed at high incidence in medullary thyroid carcinoma (MTC, 92%), small cell lung cancer (SCLC, 57%), stromal ovarian cancer (100%), astrocytomas (65%), as well as gastroenteropancreatic neuroendocrine tumours (22%), have proven to be a promising alternative approach for targeted therapy [3–5]. Here, CCKBR is linked to small cell lung carcinoma.